Loxo Oncology, Inc. (NASDAQ:LOXO) major shareholder Aisling Capital Iii Lp sold 250,000 shares of Loxo Oncology stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $80.50, for a total value of $20,125,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Aisling Capital Iii Lp also recently made the following trade(s):
- On Wednesday, November 22nd, Aisling Capital Iii Lp sold 500,000 shares of Loxo Oncology stock. The shares were sold at an average price of $75.00, for a total value of $37,500,000.00.
Shares of Loxo Oncology, Inc. (LOXO) opened at $83.46 on Friday. Loxo Oncology, Inc. has a one year low of $30.51 and a one year high of $95.92.
Several equities analysts recently commented on the company. BTIG Research reiterated a “buy” rating and issued a $102.00 target price (up from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Cowen reiterated a “buy” rating on shares of Loxo Oncology in a research note on Thursday, September 28th. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 target price (up from $95.00) on shares of Loxo Oncology in a research note on Friday, October 6th. Citigroup reissued a “buy” rating and set a $112.00 price target (up previously from $86.00) on shares of Loxo Oncology in a research report on Friday, October 20th. Finally, BidaskClub raised Loxo Oncology from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $90.57.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.